Genentech sues Biogen for debt over blockbuster MS drug

Published Date: 08 Mar 2023

Roche's Genentech Inc sued Biogen MA Inc in federal court in San Francisco, alleging that Biogen owed additional patent royalties from worldwide sales of its blockbuster multiple sclerosis and Crohn's disease drug, Tysabri.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Early PET May Help Tailor Therapy in Hodgkin Lymphoma

2.

PPI, Antibiotics May Curb Durvalumab Efficacy in NSCLC

3.

In leukemia, allogeneic HCT is beneficial following primary induction failure.

4.

Experts suggest Michelangelo depicted breast cancer in the Sistine Chapel fresco

5.

The acceptance of innovative hormonal therapy for advanced prostate cancer is racialized.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot